Patent application number | Description | Published |
20100105643 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 04-29-2010 |
20100318063 | DUAL BARREL SYRINGE ASSEMBLY - A syringe system for dispensing or injecting one or more fluids is provided. The syringe system includes a hollow body that retains cartridge(s) and/or syringe(s) each containing a fluid, such as an injectable fluid e.g., a catalyst in one cartridge and a polymer in the other. Upon use for dispensing two fluids, the syringe system mixes the two fluids immediately prior to or concurrently with the dispensing or injecting of the fluids. The syringe system can also be configured to independently dispense a single fluid or immediately dispense multiple fluids sequentially. | 12-16-2010 |
20110082543 | Methods and Devices for Preventing or Delaying Posterior Capsule Opacification - Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. A third method involves surface modifying the exterior surface of a capsular tension ring by coating or grafting the exterior surface with a charged polyethylamine and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. An implantable ocular device according to the invention, such as an intraocular lens or a capsular tension ring, contains a substrate with a chemical moiety grafted thereon and a non-cytotoxic inhibitor compound covalently bonded to the chemical moiety or contains a substrate modified with a mitotic inhibitor or charged polyethylamine. The inhibitor devices inhibits proliferation and migration of lens epithelial cells on the posterior capsule of the eye of the patient, thereby preventing, minimizing, or delaying the onset of posterior capsule opacification. | 04-07-2011 |
20110229452 | Ophthalmic Surgical Irrigating Solutions Containing Hyaluronidase - An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells. | 09-22-2011 |
20120134662 | VIEWFINDER - A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, attachment means connected to said base member for coupling the base member to an electronic device, an open-ended housing disposed on the base member, and a sighting grid disposed adjacent an open end of the open-ended housing and method for using same is provided. | 05-31-2012 |
20120189297 | Viewfinder - A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, and an open-ended housing disposed substantially perpendicular to, and offset from the base member is disclosed. The housing includes a sighting grid disposed adjacent an open end of the open-ended housing. | 07-26-2012 |
20120301128 | Viewfinder - According to an aspect of the invention, a case or slide-on unit suitable for containing an electronic device is disclosed. The case or slide-on unit incorporates a viewfinder housing assembly that allows a user to view an image when taking a picture with the electronic device. The housing assembly includes a sighting grid that allows a user to orient an image within a field of view in order to properly capture the image | 11-29-2012 |
20120316143 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 12-13-2012 |